# ATRA and Carfilzomib in Plasma Cell Myeloma Patients

> **NCT06536413** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 42 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** All-Trans Retinoic Acid (ATRA) Dose 0
- **DRUG:** All-Trans Retinoic Acid (ATRA) Dose -1
- **DRUG:** All-Trans Retinoic Acid (ATRA) Dose 1

## Key facts

- **NCT ID:** NCT06536413
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-29
- **Primary completion:** 2029-07
- **Final completion:** 2030-07
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536413, "ATRA and Carfilzomib in Plasma Cell Myeloma Patients". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06536413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*